A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Phoenix/Scottsdale, Ariz., Rochester, Minn.
Trial status: Open for Enrollment
Why is this study being done?
This is a randomized, double blinded, prospective study. Subjects will be evaluated and randomized to a treatment group if they qualify for the study. Subjects will receive either a device or sham procedure. Throughout the study glycemic control and various laboratory tests will be evaluated. A comparison of glycemic control between the two groups will be assessed as the primary outcome measurement.
Who is eligible to participate?
- HbA1c ≥ 7.5% and ≤ 10%
- BMI ≥ 30 and ≤ 55
- Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis
- C-peptide < 1.0 ng/mL
- Previous GI surgery or abnormal GI anatomical finding
- Prescription antithrombotic therapy (e.g. anticoagulant or antiplatelet agent)